Key Stats for DENTSPLY Stock
- This Week Performance: -7.4%
- 52-Week Range: $9.9 to $17.2
- Current Price: $11.8
What Happened?
Dentsply Sirona (XRAY), a global dental products maker now trading at $11.80, is attempting its most aggressive commercial reset in years after FY 2025 net sales of $3.68 billion missed the growth trajectory investors expected and a $144 million impairment charge confirmed the depth of the hole in implants and connected technology.
Also, CEO Dan Scavilla unveiled a restructuring targeting $120 million in annualized savings alongside the elimination of the quarterly dividend, redirecting roughly $128 million annually toward debt retirement and share repurchases, with FY 2026 guidance set at $3.5 billion to $3.6 billion in net sales and adjusted EPS of $1.40 to $1.50.
Q4 2025 net sales of $961 million rose 6.2% on an easy comparable inflated by a one-time Byte refund and pre-buy tailwind, but adjusted EBITDA margin contracted 10 basis points to 14.1% as $15 million in tariff headwinds and volume losses in implants and CAD/CAM, the computer-aided design and manufacturing systems that anchor the company’s premium equipment segment, exposed the fragility of the recovery.
Scavilla stated at the February 26 earnings call that “we are going deeper, moving faster and being bolder to drive sustained profitable growth,” anchoring the claim to a 50% increase in clinical education spending and a double-digit lift in R&D as a percentage of sales, rising from approximately 4% toward a 5% to 6% target.
With $120 million in restructuring savings to reinvest, three new board members including former Patterson CEO Don Zurbay and former IDEXX CFO Brian McKeon sharpening governance, an FDA-cleared dental MRI system developed with Siemens Healthineers, and the Implant Solutions World Summit scheduled for June 25 in Gothenburg, Dentsply is stacking near-term catalysts against a 24-month Return-to-Growth plan designed to restore U.S. implant market share and unlock the full commercial potential of DS Core, its connected dentistry platform.
Wall Street’s Take on XRAY Stock
The $120 million restructuring and dividend elimination announced February 26 directly attack the free cash flow collapse that sent XRAY’s FCF from $280 million in 2024 to just $104 million in 2025, a 63% single-year drop.
Consensus estimates project FCF nearly doubling to $210 million in 2026 as restructuring savings flow through, with FCF margin recovering from 2.8% to 5.8%, supported by the drop-ship model transition reducing dealer inventory distortions worth roughly $30 million.
Wall Street remains cautious but is quietly lifting targets: 15 analysts now cover XRAY with 2 buys, 1 outperform, 14 holds, and 1 underperform, and the mean price target of $14.43 implies 22.3% upside from the current $11.80.
The target spread runs from $12.00 on the low end to $18.00 on the high end, where the bear case hinges on continued U.S. implant volume deterioration and the bull case requires the Return-to-Growth dealer channel expansion to convert pipeline into fourth-quarter revenue.
What Does the Valuation Model Say?
The TIKR mid-case model prices in a target of $15.67 per share, implying 32.8% total return, anchored to a revenue CAGR of just 1.4% and FCF margin recovery toward 10.1% by 2029. The model does not require a market recovery, only disciplined execution of the restructuring already underway.
The market prices XRAY as a structurally broken business, yet the TIKR model needs only 1.4% revenue CAGR to deliver 32.8% total return, making this a margin story, not a growth story.
The operational evidence is already arriving: the commercial reorganization completed by end of Q1 2026 and new agreements with Patterson, Benco, Burkhart, and A-dec position the CTS segment, Dentsply’s connected equipment business, for a second-half revenue inflection.
Director Gregory Lucier and newly appointed director James Forbes both acquired shares on March 3, signaling board-level conviction at current prices ahead of any visible fundamental improvement.
The key risk is China: volume-based procurement phase two in 2026 has already compressed implant volumes to a double-digit decline in H2 2025, and a prolonged policy drag breaks the EBITDA margin recovery assumption underpinning the model’s $15.67 target.
Watch Q2 2026 earnings for the first clean read on U.S. implant volumes and CTS equipment sell-through, specifically whether the $30 million dealer inventory clears on schedule and whether adjusted EBITDA margin holds above 14%.
Should You Invest in DENTSPLY SIRONA Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up XRAY stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track DENTSPLY SIRONA Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze XRAY stock on TIKR for Free →
